StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$93.81−5.56 (-5.60%)

Close on Nov 17, 2026Market cap $8.27BP/E –Yield –

Spyre Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Spyre Therapeutics's operating margin for the twelve months ending Mar 31, 2024 was -39428.9%. For fiscal 2023 it was -27348.0%, against -3640.2% the year before. The highest annual figure on record is -350.3% in fiscal 2021.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-27348.0%−23707.7
FY2022Dec 31, 2022-3640.2%−3289.9
FY2021Dec 31, 2021-350.3%+819.0
FY2018Dec 31, 2018-1169.3%−637.6
FY2017Dec 31, 2017-531.7%−58.4
FY2016Dec 31, 2016-473.3%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2023Jun 30, 2023-23146.2%−19558.5
Q1 FY2023Mar 31, 2023-9498.0%−7703.5
Q4 FY2022Dec 31, 2022-11406.0%−10845.0
Q3 FY2022Sep 30, 2022-10778.7%−9328.2
Q2 FY2022Jun 30, 2022-3587.7%−3538.7
Q1 FY2022Mar 31, 2022-1794.5%−1387.8
Q4 FY2021Dec 31, 2021-561.0%−15.0
Q3 FY2021Sep 30, 2021-1450.5%−1003.7
Q2 FY2021Jun 30, 2021-49.0%+585.3
Q2 FY2018Jun 30, 2018-406.6%+47.7
Q1 FY2018Mar 31, 2018-546.0%+98.7
Q4 FY2017Dec 31, 2017-446.9%–
Q3 FY2017Sep 30, 2017-634.3%–
Q2 FY2017Jun 30, 2017-454.4%–
Q1 FY2017Mar 31, 2017-644.7%–

More Spyre Therapeutics figures

See a number that looks wrong?